Dulgar, O. Et Al. 2022. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?. EXPERT REVIEW OF ANTICANCER THERAPY , vol.22, no.7 , 773-780.

Dulgar, O., Oven, B. B., Atci, M. M., Arikan, R., Ay, S., Ayhan, M., ... Selvi, O.(2022). Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?. EXPERT REVIEW OF ANTICANCER THERAPY , vol.22, no.7, 773-780.

Dulgar, Ozgecan Et Al. "Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?," EXPERT REVIEW OF ANTICANCER THERAPY , vol.22, no.7, 773-780, 2022

Dulgar, Ozgecan Et Al. "Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?." EXPERT REVIEW OF ANTICANCER THERAPY , vol.22, no.7, pp.773-780, 2022

Dulgar, O. Et Al. (2022) . "Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?." EXPERT REVIEW OF ANTICANCER THERAPY , vol.22, no.7, pp.773-780.

@article{article, author={Ozgecan Dulgar Et Al. }, title={Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?}, journal={EXPERT REVIEW OF ANTICANCER THERAPY}, year=2022, pages={773-780} }